Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010 - GBI Research Reports

Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010

Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010 - GBI Research Reports
Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010
Published Aug 01, 2011
118 pages — Published Aug 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010, which provides insights into the global vaccines market, forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines R&D pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts.

GBI Researchs analysis shows that the overall global vaccines market was valued at $28 billion in 2010. The market is expected to witness growth at a CAGR of 11.5% for the forecast period, and will reach $56.7 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage, and those in the later stages of development. The top pharmaceutical companies in the vaccines market are GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & Co. Inc, and SP-MSD. Approximately 88% of the market is covered by these six companies.

Scope

- Data and analysis on the global adult and adolescent vaccines market
- Annualized market data for the adult and adolescent vaccines market from 2007 to 2017 for pneumococcal vaccines, human pappilomavirus vaccines, seasonal flu vaccines, hepatitis A vaccines and hepatitis B vaccines
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global vaccines market
- Key M&A activities, licensing agreements and co-development deals that took place in the vaccines market between 2009 and 2011.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Devise a more tailored country strategy through the understanding of key drivers and barriers of the vaccines market.
- Develop key strategic initiatives by understanding the key focus areas and leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

  
Source:
Document ID
GBIHC146MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents38
  List of Tables72
  List of Figures92
Adult and Adolescent Vaccines Market to 2017: Introduction112
  Overview111
  GBI Research Report Guidance121
Adult and Adolescent Vaccines Market to 2017: Market Overview132
  Vaccine Preventable Diseases131
  Vaccine Manufacturing Process141
Adult and Adolescent Vaccines Market to 2017: Global Vaccines Market1514
  Market Forecasts152
  Market Share by Diseases Sector171
  Market Share by Geography181
  Average Cost of Vaccination per Child191
  Target Population193
  Immunization Coverage222
  Unmet Needs241
  Market Trends251
    Immunization Programs251
    Public Private Partnerships251
    Production Capacity261
    Reimbursements261
  Drivers261
    Growth will be Driven by Vaccines Targeting New Diseases271
    The Adult Vaccines Segment will Provide a Significant Boost to Growth of the Market271
    Pediatric Combination Vaccines will Continue to Drive Growth271
    Availability of Vaccine Technologies That Help Increase Efficacy and Safety will Drive Innovation and Growth271
    Cancer and HIV/AIDS Vaccines Hold Significant Potential for the Future271
  Barriers281
    Limitations in Production Capacity Delay the Realization of Potential281
    High Initial Capital Investments and Technical Expertise Act as Entry Barriers281
    Lack of Harmonized Regulations Delays Vaccine Launch and Acceptance281
Adult and Adolescent Vaccines Market to 2017: The US Vaccines Market297
  Market Overview291
  Market Forecasts292
  Cost of Vaccination per Child in the US311
  Immunization Schedule321
  Regulatory Framework331
  Vaccine Procurement341
  Vaccine Stockpiling351
Adult and Adolescent Vaccines Market to 2017: European Vaccines Market3612
  Market Overview361
  Market Forecasts362
  Average Cost of Vaccination per Child381
  Vaccine Stockpiling381
  The UK391
    Immunization Schedule391
    Regulatory Framework391
    Vaccine Procurement391
  France401
    Immunization Schedule401
    Regulatory Framework411
    Vaccine Procurement411
  Germany421
    Immunization Schedule421
    Regulatory Framework431
    Vaccine Procurement441
  Italy441
    Immunization Schedule441
    Regulatory Framework441
    Vaccine Procurement451
  Spain451
    Immunization Schedule451
    Regulatory Framework461
    Vaccine Procurement471
Adult and Adolescent Vaccines Market to 2017: Rest of the World Vaccines Market483
  Market Overview481
  Market Forecasts481
  Average Cost of Vaccination per Child491
  Immunization Schedule491
  Regulatory Framework491
  Vaccine Procurement491
  Vaccine Stockpiling501
Adult and Adolescent Vaccines Market to 2017: Pneumococcal Vaccines Market518
  Market Overview511
  Market Forecasts511
  Average Cost of Vaccination521
  Target Population531
  Immunization Coverage541
  Product Analysis541
    Prevnar 7541
      Overview541
      Efficacy541
      Annual Cost of Therapy541
    Prevnar 13 (pneumococcal 13-valent conjugate vaccine)541
      Overview541
      Efficacy551
      Annual Cost of Therapy551
    Pneumovax 23551
      Overview551
      Efficacy551
      Annual Cost of Therapy561
    Synflorix561
      Overview561
      Efficacy561
      Annual Cost of Therapy561
  Vaccine Pipeline Analysis571
    Phase lll571
    Phase ll581
    Phase l581
    Preclinical/Discovery581
Adult and Adolescent Vaccines Market to 2017: Human Pappilomavirus Vaccines Market598
  Market Overview591
  Market Forecasts591
  Average Cost of Vaccination601
  Target Population611
  Immunization Coverage621
  Product Analysis621
    Gardasil621
      Overview621
      Indications621
      Mechanism of Action621
      Dosage631
    Cervarix631
      Overview631
      Indications631
      Mechanism of Action631
      Dosage631
  Vaccine Pipeline Analysis631
    Phase lll631
    Phase ll641
    Phase l651
    Preclinical/Discovery661
Adult and Adolescent Vaccines Market to 2017: Seasonal Flu Vaccines Market6712
  Market Overview674
  Average Cost of Vaccination711
  Target Population721
  Immunization Coverage731
  Product Analysis731
    Fluzone731
      Overview731
      Indications731
      Dosage731
    Fluarix731
      Overview731
      Indications731
      Dosage731
  Vaccine Pipeline Analysis741
    Regulatory Filed Products741
    Phase lll741
    Phase ll751
    Phase l761
    Preclinical/Discovery772
Adult and Adolescent Vaccines Market to 2017: Hepatitis A Vaccines Market797
  Market Overview791
  Market Forecasts791
  Average Cost of Vaccination801
  Target Population811
  Product Analysis821
    Twinrix821
      Overview821
      Efficacy821
      Safety821
      Pricing821
      Clinical Study Details821
    Havrix831
      Overview831
      Efficacy831
      Annual Cost of Therapy831
    Vaqta831
      Overview831
      Efficacy831
    Ambirix841
      Overview841
      Efficacy841
      Annual cost of therapy841
    Avaxim841
      Overview841
      Efficacy841
  Vaccine Pipeline Analysis851
    NDA Filed Molecules851
    Phase lll851
    Preclinical/Discovery851
Adult and Adolescent Vaccines Market to 2017: Hepatitis B Vaccines Market869
  Market Overview861
  Market Forecasts871
  Average Cost of Vaccination881
  Target Population891
  Product Analysis901
    Recombivax HB901
      Overview901
      Efficacy901
      Pricing901
    Engerix-B901
      Overview901
      Efficacy901
      Pricing901
    Twinrix911
      Overview911
      Efficacy911
      Pricing911
    Comvax911
      Overview911
      Efficacy911
      Pricing911
  Vaccine Pipeline Analysis911
    Regulatory Filed Products911
    Phase lll921
    Phase ll931
    Phase l931
    Preclinical/Discovery941
Adult and Adolescent Vaccines Market to 2017: Competitive Landscape953
  Overview951
  Market Share Analysis962
Adult and Adolescent Vaccines Market to 2017: Strategic Consolidations9815
  Mergers &Acquisitions981
    Overview981
    Top Deals in M&A981
    M&A by Indication991
    M&A by Year1001
    M&A by Geography1011
    M&A by Value1021
  Licensing Agreements1031
    Overview1031
    Top Licensing Deals1031
    Licensing Deals by Indication1041
    Licensing Deals by Year1051
    Licensing Deals by Geography1061
    Licensing Deals by Value1071
  Co-Development Deals1081
    Overview1081
    Top Co-Development Deals1081
    Co-Development Deals by Indication1091
    Co-Development Deals by Year1101
    Co-Development Deals by Geography1111
    Co-Development Deals by Value1121
Appendix1136
  Market Definitions1131
  Abbreviations1131
  Research Methodology1141
  Global Vaccines Market1142
    Coverage1141
    Sources of Coverage1151
    Methodology1151
  Geographical Landscape1151
    Coverage1151
    Sources of Coverage1151
    Methodology1151
  Market Characterization1161
    Coverage1161
    Sources of Coverage1161
    Methodology1161
  Competitive Landscape1162
    Coverage1161
    Sources of Coverage1161
    Methodology1171
  Pipeline Analysis1171
    Coverage1171
    Sources of Coverage1171
    Methodology1171

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010" Aug 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Adult-and-Adolescent-Vaccines-Market-to-2017-Partnerships-Increase-as-Licensing-and-Co-Development-Account-for-73-of-all-Deal-Making-Activity-in-2010-2115-241>
  
APA:
GBI Research Reports. (2011). Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010 Aug 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Adult-and-Adolescent-Vaccines-Market-to-2017-Partnerships-Increase-as-Licensing-and-Co-Development-Account-for-73-of-all-Deal-Making-Activity-in-2010-2115-241>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.